ǥ :
|
ȣ - 520929 183 |
Safety and Efficacy of Pitavastatin (Livalo®) in Patients with Acute Myocardial Infarction in an Asian Population (Livalo-AMI Study; LAMIS |
고려대학교 구로병원 순환기내과 |
나승운, 윤향란1, 정명호2, 홍영준2, 안태훈3, 배장호4, 허승호5, 채인호6, 김종현7, 윤경호8, |
Background: Statin therapy, specifically a lipophilic statin Pitavastatin (Livalo) in acute myocardial infarction (AMI) may play an important role by not only reducing LDL-cholesterol, but also by the pleiotrophic effects. We studied efficacy and safety of routine administration of Pitavastatin in AMI pts as a substudy of Korea AMI Registry (KAMIR).
Methods:Study consisted of 895 consecutive AMI patients (pts; male 657, 73.4 %; age 62.1±13.1) presented in 10 major percutaneous coronary intervention (PCI) centers from April 2007 to July 2008. Pitavastatin (Livalo) 2mg/day was routinely administered from presentation. We investigated change in lipid profiles and biochemical markers at baseline, 1, 6 and 12 months, the clinical outcomes up to 1 year and adverse effects.
Result: Baseline characteristics showed diabetes in 24.6%, hyperlipidemia in 9.0% and smoking 46.6%. Among the 895 enrolled pts, STEMI was 64.6% and PCI was performed in 87.0%. Stent was deployed in 96.6% pts and success rate was 91.0%. Lipid profiles and inflammatory markers significantly improved with time. At 12 months, including one CABG pt, 12-month total major adverse cardiac event (MACE) was 43/890 pts (4.8%) without obvious myopathy or liver function deterioration cases (Table).
Conclusion: Routine administration of 2mg Pitavastatin daily in pts with AMI showed excellent biochemical and clinical outcomes without significant adverse effects.
|
Table: Results of Livalo-AMI study (N=890 pts)
Variable |
Pre-discharge |
1 month |
6 month |
12 month |
LDL-Cholesterol |
124.0±35.5 |
86.2±30.6 |
89.3±24.2 |
86.7±22.9 |
HDL-Cholesterol |
45.6±12.3 |
45.3±11.6 |
45.9±24.2 |
47.9±12.3 |
hs CRP |
12.6±35.5 |
3.5±10.3 |
5.2±18.1 |
2.0±4.2 |
Max CPK |
1188.5±1955.0 |
127.9±495.1 |
117.4±83.2 |
86.0±30.8 |
GOT (ALT) |
92.5±136.7 |
31.0±98.7 |
25.4±16.5 |
27.3±16.0 |
Total Death, cummulative |
0 |
2 |
4 |
4 |
MI, n |
0 |
1 |
12 |
19 |
Repeat PCI, n |
0 |
1 |
16 |
19 |
MACE, n |
0 |
8 |
30 |
42 |
|
|
|